Biotechnology Capital Inflows Reach Historic Highs
Brian Skorney is one of Robert W. Baird & Co.’s Senior Analysts covering biotechnology. Mr. Skorney has followed the sector for six years, most recently at Brean Murray Carret & Co. Prior to his career in equity research, Mr. Skorney worked in medical research. Mr. Skorney received a B.S. in biological sciences from the University of Notre Dame and an MBA in finance from the Stern School of Business at New York University. Profile
TWST: When we spoke a year or so ago, you were still in the process of ramping up your coverage for Baird. Bring us up to speed on your universe now. Do you still focus on hepatitis C?